Expertise in
43
conditions

Dr. Ziad H. Younes

Gastroenterology
Gastro One-Wolf River Blvd
8000 Wolf River Blvd Ste 200, 
Germantown, TN 
Accepting New Patients
Offers Telehealth
Expertise in
43
conditions
Gastro One-Wolf River Blvd
8000 Wolf River Blvd Ste 200, 
Germantown, TN 

Overview

Ziad Younes is a Gastroenterologist practicing medicine in Germantown, Tennessee.

Dr. Younes is highly rated in 43 conditions, according to our data. His clinical expertise encompasses Nonalcoholic Steatohepatitis (NASH), Crohn's Disease, Non-Alcoholic Fatty Liver Disease, Gastrectomy, and Endoscopy.

He is actively involved in clinical research, co-authoring 39 peer reviewed articles and participating in 30 clinical trials. Dr. Younes is currently accepting new patients.

Specialties

Gastroenterology

Licenses

Internal Medicine in TN

Hospital Affiliations

Methodist Hospitals Of Memphis
Baptist Memorial Hospital
St Francis Hospital

Languages Spoken

English
Arabic

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Arkansas Health and Wellness
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Farm Bureau Health Plans
  • HMO
  • MEDICARE MAPD
  • MEDICARE PDP
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Magnolia Health
  • HMO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 17 Less Insurance Carriers -

Locations

Gastro One-Wolf River Blvd
8000 Wolf River Blvd Ste 200, Germantown, TN 38138

Additional Areas of Focus

Dr. Younes has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

28 Clinical Trials

A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients With Crohn's Disease
A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients With Crohn's Disease
Enrollment Status: Active_not_recruiting
Publish Date: August 11, 2026
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis
A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis
Enrollment Status: Terminated
Publish Date: June 30, 2026
Intervention Type: Drug
Study Drug: Belapectin
Study Phase: Phase 2/Phase 3
Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode
Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode
Enrollment Status: Active_not_recruiting
Publish Date: May 14, 2026
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Enrollment Status: Completed
Publish Date: May 13, 2026
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2026
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk
ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2025
Intervention Type: Device, Diagnostic test
Blood and Stool Sample Collection in Subjects With a Diagnosis of Colorectal Cancer or Colorectal Lesion: Act Fast
Blood and Stool Sample Collection in Subjects With a Diagnosis of Colorectal Cancer or Colorectal Lesion: Act Fast
Enrollment Status: Completed
Publish Date: June 29, 2025
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Enrollment Status: Completed
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Open-label Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Subjects With Eosinophilic Esophagitis (EoE)
A Phase 3, Multicenter, Open-label Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Subjects With Eosinophilic Esophagitis (EoE)
Enrollment Status: Terminated
Publish Date: February 19, 2025
Intervention Type: Drug
Study Drug: Budesonide oral suspension
Study Phase: Phase 3
A Phase 3, Multicenter, Double-blind Extension Study to Evaluate Maintenance of Efficacy of Oral Budesonide Suspension (OBS) and Long-term Treatment Effect of OBS in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis (EoE)
A Phase 3, Multicenter, Double-blind Extension Study to Evaluate Maintenance of Efficacy of Oral Budesonide Suspension (OBS) and Long-term Treatment Effect of OBS in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis (EoE)
Enrollment Status: Completed
Publish Date: February 19, 2025
Intervention Type: Drug
Study Phase: Phase 3
View 9 Less Clinical Trials

39 Total Publications

Mirikizumab is associated with rapid and sustained improvements in novel measures of bowel urgency in moderately-to-severely active ulcerative colitis: 28-week results from the LUCENT-URGE trial.
Mirikizumab is associated with rapid and sustained improvements in novel measures of bowel urgency in moderately-to-severely active ulcerative colitis: 28-week results from the LUCENT-URGE trial.
Journal: Journal of Crohn's & colitis
Published: May 11, 2026
Similar Doctors
Expertise in
15
conditions
Dr. Mansour A. Parsi
Gastroenterology
Expertise in
15
conditions
Dr. Mansour A. Parsi
Gastroenterology
Referral may be required

Regional One Health Pharmacy

880 Madison Ave, 
Memphis, TN 
 (13.8 miles away)
901-545-6969
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Mansour Parsi is a Gastroenterologist practicing medicine in Memphis, Tennessee. Dr. Parsi is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Bile Duct Stricture, Cholangitis, Choledocholithiasis, Endoscopy, and Lithotripsy. Dr. Parsi is currently accepting new patients.

Expertise in
9
conditions
Dr. Colin W. Howden
Gastroenterology
Expertise in
9
conditions
Dr. Colin W. Howden
Gastroenterology
Referral may be required

Regional One Health

877 Jefferson Ave, 
Memphis, TN 
 (13.7 miles away)
901-545-8400
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Colin Howden is a Gastroenterologist practicing medicine in Memphis, Tennessee. Dr. Howden is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Helicobacter Pylori Infection, Indigestion, Gastroesophageal Reflux Disease (GERD), Endoscopy, and Colonoscopy. Dr. Howden is currently accepting new patients.

Expertise in
44
conditions
Dr. Gary A. Wruble
Gastroenterology
Expertise in
44
conditions
Dr. Gary A. Wruble
Gastroenterology
Referral may be required

Office

1324 Wolf Park Dr, 
Germantown, TN 
 (2.0 miles away)
901-755-9110
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Gary Wruble is a Gastroenterologist practicing medicine in Germantown, Tennessee. Dr. Wruble is highly rated in 44 conditions, according to our data. His clinical expertise encompasses Ulcerative Colitis, Gastroesophageal Reflux Disease (GERD), Crohn's Disease, Endoscopy, and Colonoscopy. Dr. Wruble is currently accepting new patients.

Frequently Asked Questions about Dr. Ziad H. Younes

How do I make an appointment with Dr. Ziad H. Younes?

You can book an appointment with Dr. Ziad H. Younes by calling their office at 901-747-3630. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Ziad H. Younes a top-rated expert for Nonalcoholic Steatohepatitis (NASH)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Ziad H. Younes is classified as an Distinguished expert for Nonalcoholic Steatohepatitis (NASH), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Ziad H. Younes specialize in?

While Dr. Ziad H. Younes is a Gastroenterology, they have specific expertise in Nonalcoholic Steatohepatitis (NASH), Crohn's Disease, and Non-Alcoholic Fatty Liver Disease. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Gastroenterology.

Does Dr. Ziad H. Younes participate in research or clinical trials?

Yes. Dr. Ziad H. Younes has published 39 articles and abstracts on conditions like Nonalcoholic Steatohepatitis (NASH). You can view a list of Dr. Ziad H. Younes's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Ziad H. Younes accept my insurance?

Dr. Ziad H. Younes accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 901-747-3630 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Younes's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 36 Advanced Conditions
    View All 59 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile